Introduction
============

Cardiovascular diseases (CVD) are the leading causes of death among adults in the industrialized world (29.2% of total global deaths) and in developing countries, and will probably remain so in the near future ([@b90]). Hypertension is one of the most prevalent risk factors for the development of cardiovascular complications such as left ventricular hypertrophy, myocardial infarction, stroke, and renal diseases. However, if blood pressure (BP) is effectively controlled, target-organ damage can be prevented and, in the long term, the likelihood of these complications can be reduced ([@b16]; [@b17]). Its treatment is also one of the most effective ways to retard the progression of diabetic and non-diabetic renal diseases ([@b16]; [@b17]). Unfortunately, reports from several countries around the world have shown that hypertensive patients with well-controlled BP represent only a small percentage of the hypertensive population (usually less than 30%). This contrasts with the rather high response rate obtained in clinical trials investigating new antihypertensive drugs or therapeutic strategies. For example, in the Hypertension Optimal Treatment (HOT) study, 88% of patients assigned to a target diastolic BP ≤90 mmHg achieved this goal after 12 months of antihypertensive treatment ([@b33]). In the ALLHAT study, \>60% of the enrolled patients achieved a BP goal \<140/90 mmHg at 5 years ([@b80]). This apparent discrepancy between the results obtained in the general hypertensive population and those of large clinical trials is perhaps explained by the experimental conditions in which clinical trials are conducted and by the selection of patients and physicians both being more motivated or willing to achieve target BP levels when engaged in clinical studies ([@b65]). Nevertheless, it strongly suggests that it should be possible to increase the overall percentage of patients reaching a satisfactory BP control.

Today, when the patient fails to respond to treatment, the most common medical response is to increase the dose of the antihypertensive agent, to add another drug, or eventually to change the therapeutic agent ([@b87]). In some cases, clinical investigations looking for a secondary form of hypertension will be conducted. Thus, physicians have a systematic bias considering that the patient is basically a non-responder or that the pharmacological regimen is inadequate. This "pharmacological" attitude leads either to the use of high doses of antihypertensive agents which are very likely to produce side-effects, or to the prescription of several antihypertensive compounds according to the classical step-care therapy scheme. However, both the occurrence of side-effects and the increased complexity of the regimen have been shown to reduce drug adherence and the persistence of treatment ([@b98]).

Treating hypertension with a combination of different drugs has multiple rationale and advantages and might offer the possibility to reduce the number of non-responders. The first advantage is obviously to associate drugs with different mechanisms of action leading to an increased efficacy of each individual drug. Another potential clinical interest of drug combinations is to blunt the activation of physiological compensatory feed-back mechanisms which could either interfere with the activity of a drug or generate side-effects. Thus, combining two agents that may mutually interfere with compensatory responses is more likely to increase the BP control rate ([@b87]) and may even prevent side-effects. Studies have clearly demonstrated that BP can be readily controlled in almost two-thirds of the cases by a carefully selected prescription of two drugs ([@b74]; [@b25]).

In this context, the association of a blocker of the renin-angiotensin system (RAS) with a diuretic is a very logical combination. The natriuretic effect of the diuretic which leads to a decrease in plasma volume stimulates renin secretion and thereby increases angiotensin II and aldosterone production, which in turn causes vasoconstriction and promotes water and sodium retention. The direct consequence of these physiological responses is a limitation of the antihypertensive effect of the diuretic. Blockade of the RAS in such high-renin conditions prevents the angiotensin II-dependent BP maintenance ([@b14]) and thus enhances the effect of the diuretic ([@b60]). Conversely, the antihypertensive efficacy of blockers of the RAS is blunted when patients are salt-loaded because BP becomes volume- rather than renin-dependent. With the addition of a diuretic, BP becomes more renin-dependent and the antihypertensive efficacy of the blocker of the RAS is increased by the diuretic. This explains why a large number of fixed-dose combinations containing RAS blocker and a diuretic have been developed in the past. Clinical as well as experimental studies have demonstrated that when combined with hydrochlorothiazide, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) lower BP in low-, normal-, and high-renin hypertension ([@b87]). The interest in these combinations is particularly evident in black populations, in whom a monotherapy with conventional doses of an ACEI or an ARB is often considered less effective unless patients are maintained on a low-sodium intake ([@b26]). Another advantage of such a combination is also its excellent tolerability profile with a very low incidence of adverse effects, as will be discussed below.

Telmisartan/hydrochlorothiazide: fixed-dose combination
=======================================================

Introduction to the compounds
-----------------------------

The ARB telmisartan and the thiazide diuretic hydrochlorothiazide are two antihypertensive agents that have a well-recognized clinical efficacy in the treatment of hypertension ([@b82]; [@b1]; [@b57], [@b60]; [@b52]; [@b59]). However, as generally observed in the treatment of essential hypertension, many patients are either from the time of diagnosis or later in their follow-up, insufficiently controlled with telmisartan or hydrochlorothiazide alone ([@b42]; [@b38]; [@b40]; [@b28]). Therefore, fixed-doses combination of telmisartan and hydrochlorothiazide (Micardis-Plus^®^ and Micardis/HCT^®^, Boehringer Ingelheim, or PritorPlus^®^, GlaxoSmithKline) have been developed in order to further improve the efficacy of telmisartan and to promote compliance in patient who otherwise would require the administration of two drugs. Combined therapy is available in three combinations of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg telmisartan and hydrochlorothiazide, respectively.

Chemistry, pharmacology, pharmacodynamics, and pharmacokinetics of the compounds
--------------------------------------------------------------------------------

Telmisartan is a long-acting, nonpeptide angiotensin II receptor-subtype 1 (AT~1~) antagonist, which is orally active, highly selective, and potent. It is chemically described as 4′-\[(1,4′-dimethyl--2′-propyl\[2,6′-bi-1H-benzimidazol\] 1′-yl)methyl\]-\[1,1′-bipheny\]-2-carboxylic acid. Telmisartan has the molecular formula C~33~H~30~N~4~O~2~; its molecular weight is 514.6 g/mol. It is a relatively lipophilic compound and has a higher *n*-octanol/buffer partition coefficient (log p = 3.20) than candesartan (−0.96), irbesartan (1.48), valsartan (−0.95), or EXP-3174 (−2.45), the active metabolite of losartan ([@b92]). This high lipophilicity that is also reflected in its high volume of distribution (c. 500 L) ([@b76]) enhances tissue penetration, intracellular absorption, and bioavailability ([@b92]).

Telmisartan lacks the tetrazole unit which is usually present in the structure of sartans, but has a common benzimidazole group with candesartan. The substitution of this benzimidazole moiety with a basic heterocycle results in potent AT~1~ antagonism and good absorption after oral administration ([@b67]). Telmisartan selectively and insurmountably inhibits stimulation of the AT~1~ receptor by angiotensin II without affecting other receptor systems involved in cardiovascular regulation. It inhibits the binding of labeled angiotensin II to AT~1~ receptors in rat lung with a K~i~ of 3.7 nmol/L ([@b93]). The drug dissociates slowly from AT~1~ receptors with a dissociation half-life of about 75 minutes compared with 14.5 minutes for angiotensin II, and there appears to be no re-association of telmisartan with the receptor ([@b46]). This feature may explain why telmisartan has the longest half-life (approximately 24 hours) of all commercially available ARBs ([@b45]), making it suitable for once-daily dosing ([@b61]). Telmisartan blunts all the AT~1~-mediated effect of angiotensin II, including the vasoconstrictor and aldosterone-secreting effect of angiotensin II. It also inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increases in plasma renin activity and angiotensin II circulating levels do not overcome the blockade exerted by telmisartan ([@b77]; [@b19]). In addition to its vasodilatory properties, telmisartan also appears to modulate renal function, an effect which may contribute to its antihypertensive efficacy and has been demonstrated in vitro on isolated perfused kidneys ([@b93]) as well as in vivo in rats and dogs ([@b91]; [@b68]). Finally, In addition to its AT~1~ receptor antagonism, telmisartan has also been identified as an activator of the peroxisome proliferator-activated receptor γ (PPAR-γ) ([@b6]; [@b71]). The transcription factor PPAR-γ is a nuclear hormone receptor, which acts as a central regulator of insulin and glucose metabolism, improving insulin sensitivity. Full receptor agonists such as the thiazolidinidiones pioglitazone (Actos^®^; Eli Lilly) or rosiglitazone (Avendia^®^; GlaxoSmithKline) are approved for the indication of diabetes mellitus ([@b64]). Unfortunately, besides their insulin-sensitizing effect these drugs also showed some adverse effects like weight gain, edema and fluid retention ([@b100]). In contrast, telmisartan showed only a partial agonistic activity for the PPAR-γ receptor and thus modulates the activity of PPAR-γ, retaining the metabolic efficacy of PPAR-γ activation with reduction in adverse effects exerting in parallel with AT~1~ receptor blockade ([@b70]). This special feature (also present though in a smaller extend in other ARBs such as irbesartan ([@b71]) and losartan ([@b49])) may provide a new therapeutic option for better cardiovascular risk management in metabolic diseases. Indeed, telmisartan that combines antihypertensive and antidiabetic actions has been found in some preclinical and clinical studies to improve carbohydrate and lipid metabolisms without causing the side effects that accompany full PPAR-γ activators ([@b37]). Yet, the clinical relevance of these effects of telmisartan on PPAR-γ receptors remains to be demonstrated on a large group of hypertensive patients.

Hydrochlorothiazide (HCTZ) is a sulfonamide derivative thiazide diuretic. Chemically it is described as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadizine-7-sulfonamide 1,1-dioxide. Its empirical formula is C~7~H~8~ClN~3~O~4~S~2~; and its molecular weight is 297.7 g/mol. Thiazide diuretics such as hydrochlorthiazide are widely used for the treatment of hypertension. Though the mechanism of the antihypertensive effect of thiazides is still not fully understood, it is obvious that these agents act by promoting sodium excretion leading to a transitory negative sodium balance. Thiazides affect the renal tubular mechanisms of electrolytes reabsorption in the distal segment of the nephron, directly increasing the excretion of sodium and chloride in approximately equivalent amounts by blocking the Na^+^Cl^−^ co-transporter. Following oral administration of hydrochlorthiazide, urinary electrolytes and water excretion increase within 2 hours, peaks at 4 hours, and the effect lasts for up to 24 hours.

Unfortunately, the drawback of such compounds is, as already mentioned, the secondary stimulation of the RAS resulting in an increase in aldosterone secretion which in turn causes a loss of potassium and a compensatory increase in proximal re-absorption of uric acid leading to hyperuricemia. These effects are responsible for two of the major side-effects of thiazide diuretics, ie, hypokalemia and gout ([@b66]). Of note, thiazide-induced hypokalemia can potentially trigger adverse cardiac events ([@b5]; [@b75]).

The pharmacokinetics and pharmacodynamic properties of the telmisartan/hydrochlorothiazide combination have not been studied extensively in patients or healthy volunteers. For example, to date, only one study has been designed to compare the steady-state pharmacokinetics of a high-dose telmisartan with and without a high-dose of hydrochlorothiazide in order to compare the steady-state pharmacokinetics of hydrochlorothiazide and telmisartan given alone or in combination. This open-label, crossover study was done in 13 healthy volunteers. All subjects received telmisartan 160 mg qd, hydrochlorothiazide 25 mg qd and telmisartan/hydrochlorothiazide 160/25 mg qd for 7 days. Each treatment phase was separated by a 14-day washout period ([@b99]). The results showed that there were no appreciable differences in trough plasma concentrations of hydrochlorothiazide and telmisartan, given alone or in combination. Mean values of the primary end points (C~max~ and AUC~0-24~) and secondary end points (C~min~ and t~1/2~) for both telmisartan and hydrochlorothiazide were unaffected when administered simultaneously. Moreover, concurrent telmisartan had no effect on urinary excretion of hydrochlorothiazide. The absence of any significant effect on the pharmacokinetics of either hydrochlorothiazide or telmisartan demonstrates that no dose adjustment is required if the two agents are given together for the management of hypertension.

In contrast to other ARBs, some drug interactions have been described with telmisartan. In particular, telmisartan increases (49% at peak and 30% at trough) serum digoxin concentration, and may also decrease plasma warfarin levels ([@b73]). The administration of telmisartan did not result in clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, ibuprofen, or hydrochlorothiazide. Since telmisartan had no effects in vitro on cytochrome P450 enzymes, except for some minimal inhibition of CYP2C19, it is not expected to interact with drugs that inhibit cytochrome P450 enzymes nor with drugs that are metabolized by cytochrome P450, except for possible inhibition for drugs metabolized by CYP2C19 ([@b81]). On the other hand, hydrochlorothiazide may potentially interact with a large variety of drugs. Thus, the absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Thiazide diuretics reduce the renal clearance of lithium and lead to a high risk of lithium toxicity.

We have summarized in [Table 1](#tbl1a){ref-type="table"} the main pharmacodynamics of telmisartan and hydrochlorothiazide separately. Indeed, apart from its antihypertensive action in rats ([@b94]), no special report has been published on the pharmacodynamic properties of the telmisartan/hydrochlorothiazide combination itself. Therefore, the properties described in this table are from studies in animals, healthy volunteers, and patients receiving telmisartan or hydrochlorothiazide as monotherapy.

###### 

Pharmacodynamic properties of telmisartan

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In vivo (animals)
  Dose-dependent inhibition of the pressor response to exogenous angiotensin II in rats ([@b15]) and dogs ([@b92])
  Reduces blood pressure observed TGR (mREN)27 transgenic rats at oral doses of \>0.5 mg/kg/day
  The compound was more potent than losartan in reducing mean arterial blood pressure in these transgenic rats ([@b82])
  Modulation of renal excretory function in isolated perfused rat kidneys ([@b93])
  Diuretic effects in rats and dogs ([@b91]; [@b68])
  Decrease glomerulosclerosis and proteinuria as well as cardiac hypertrophy in different animal models of hypertension and diabetes ([@b9], [@b10]; [@b92], [@b94])
  After peripheral administration, penetrates the blood--brain barrier of rats in a dose- and time-dependent manner to inhibit centrally mediated effects of Ang II ([@b31])
  Partial agonist of PPARγ in rats fed a high-fat, high carbohydrate diet ([@b6])
  Attenuates weight gain and decreases serum triglyceride and glucose levels vs losartan or vehicle in a rat model of diet-induced insulin resistance ([@b6])
  Decreases cardiac hypertrophy in hypertensive or diabetic rat model ([@b73])
  In vivo (humans)
  Prolonged inhibition of angiotensin II-induced increase in blood pressure in normotensive volunteers ([@b83]; [@b77])
  The \>25% inhibitory effect of telmisartan 80 mg to repeated angiotensin II challenge lasts \>40 hours in healthy subjects ([@b77])
  Increases urinary Na^+^ excretion without increasing K^+^ and uric acid excretion in drug-free hypertensive patients ([@b27])
  Decreases cardiac hypertrophy in hypertensive patients ([@b50])
  Reduces proteinuria in diabetic patients ([@b3])
  Decreases fasting insulin levels, serum triglyceride levels, high sensitivity C-reactive protein ([@b55])
  Significant decrease in left ventricular hypertrophy after 3−24 months' treatment in hypertensive patients ([@b50])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Overview of the pharmacodynamic properties of hydrochlorothiazide

  -----------------------------------------------------------------------------------------------------------------------
  Inhibits the Na^+^/Cl^−^ co-transporter in the distal convoluted tubule and thereby increase sodium excretion
  Increases excretion of potassium K^+^ and may cause hypokalemia
  Inhibits vascular smooth muscle cell carbonic anhydrase which results in an activation of potassium channels ([@b63])
  May causes extracellular volume depletion, hyponatremia, hypochloremia, metabolic alkalosis, and hypercalcemia
  Increases serum uric acid and may cause gout
  Reduces blood pressure and reduces the incidence of cardiovascular events in hypertension (ALLHAT study)
  May decrease glucose tolerance and unmask latent diabetes mellitus
  May increase plasma concentrations of low density lipoprotein, total cholesterol, and total triglycerides
  -----------------------------------------------------------------------------------------------------------------------

Clinical efficacy of telmisartan/hydrochlorothiazide
====================================================

Numerous reviews dealing with the clinical antihypertensive efficacy of telmisartan/hydrochlorothiazide have been recently published ([@b27]; [@b69]; [@b44]; [@b53]; [@b4]). A series of large, multicenter, randomized, controlled clinical trials has been performed recently in order to evaluate the clinical efficacy of this therapy (see [Table 2](#tbl2){ref-type="table"}). Different primary end points were defined in these studies: the reduction in DBP, either from baseline ([@b35]; [@b42]; [@b52]; [@b40]; [@b28]) or to values inferior to 90 mmHg ([@b58]; [@b28]); changes in ambulatory DBP and SBP ([@b38]); and decreases in supine SBP ([@b35]; [@b29]). In these controlled clinical trials with over 2500 patients, patients were exposed to telmisartan (20--160 mg) and concomitant hydrochlorothiazide (6.25--25 mg). These trials included one factorial design trial with combinations of telmisartan (20, 40, 80, 160 mg, or placebo) and hydrochlorothiazide (6.25, 13.5, 25 mg, or placebo) ([@b52]). Four other studies of at least 6 months' duration allowed the addition of hydrochlorothiazide for patients who either were not adequately controlled on the randomized monotherapy dose or had not achieved adequate response after a complete up-titration of telmisartan ([@b35]; [@b29], [@b28]; [@b58]). All these studies proved this combination both as fixed-dose combination ([@b42], [@b39]; [@b52]; [@b38]) or as an add-on ([@b29], [@b28]; [@b58]), to be highly effective in reducing BP ([@b44]), particularly in the early morning period ([@b41]). Combining telmisartan with hydrochlorothiazide enhances the antihypertensive activity of telmisartan in almost two-thirds of hypertensive patients with mild to moderate hypertension. Moreover, because of their synergism, BP control can sometimes be achieved with lower doses of each component ([@b69]; [@b44]). This is particularly interesting since the metabolic disturbances associated with high dose hydrochlorothiazide were avoided by combining low doses of this drug with telmisartan ([@b69]).

###### 

Efficacy of the telmisartan/hydrochlorothiazide (HCTZ) combination compared with that of placebo or other antihypertensive agents: changes in blood pressure in patients with mild to moderate or severe hypertension in multicenter randomized, double bind studies

  Reference             No of patients   Dosage (mg/day) \[duration (wk)\]^a^    Comparator                 Mean baseline SBP/DBP values (mmHg)   SBP/DBP mean reductions                                                           
  --------------------- ---------------- --------------------------------------- -------------------------- ------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------
  ([@b52])              223              telmisartan 80/HCTZ 12.5 \[8\]          placebo                    154/100                               23.9[\*\*](#tf2-2){ref-type="table-fn"}/14.9[\*\*](#tf2-2){ref-type="table-fn"}   vs placebo
                                                                                 telmisartan 80             153/100                               8.5[\*\*](#tf2-2){ref-type="table-fn"}/3.4[\*\*](#tf2-2){ref-type="table-fn"}     vs telmisartan 80
                                                                                 HCTZ 12.5                  153/100                               17.0[\*\*](#tf2-2){ref-type="table-fn"}/7.6[\*\*](#tf2-2){ref-type="table-fn"}    vs HCTZ 12.5
                                                                                 telmisartan 40/HCTZ 12.5   154/100                               5.1[\*](#tf2-1){ref-type="table-fn"}/2.3[\*](#tf2-1){ref-type="table-fn"}         vs telmisartan 40/HCTZ 12.5
                        291              telmisartan 40/HCTZ 12.5 \[8\]          placebo                    154/100                               18.8[\*\*](#tf2-2){ref-type="table-fn"}/12.6[\*\*](#tf2-2){ref-type="table-fn"}   vs placebo
                                                                                 telmisartan 40             153/100                               6.6[\*\*](#tf2-2){ref-type="table-fn"}/1.9^ns^                                    vs telmisartan 40
                                                                                 HCTZ 12.5                  153/100                               11.9[\*\*](#tf2-2){ref-type="table-fn"}/5.3^ns^                                   vs HCTZ 12.5
  ([@b40])              327              telmisartan 40/HCTZ 12.5 \[8\]                                     147/96                                7.4[\*\*](#tf2-2){ref-type="table-fn"}/3.5[\*\*](#tf2-2){ref-type="table-fn"}     vs telmisartan 40
  ([@b42])              491              telmisartan 80/HCTZ 12.5 \[8\]                                     NR/\>90                               5.7[\*\*](#tf2-2){ref-type="table-fn"}/3.1[\*\*](#tf2-2){ref-type="table-fn"}     vs telmisartan 80
  ([@b39])              597              telmisartan 80/HCTZ 12.5 \[6\]          losartan 50/HCTZ 12.5      140/95-200/114                        NR/2.5[\*\*](#tf2-2){ref-type="table-fn"}                                         vs losartan 50/HCTZ 12.5
                                         telmisartan 40/HCTZ 12.5 \[6\]                                                                           NR/1.8[\*](#tf2-1){ref-type="table-fn"}                                           vs losartan 50/HCTZ 12.5
  ([@b51])              222              telmisartan 80/HCTZ 12.5 \[8\]          placebo                    154/100                               21.5[\*\*](#tf2-2){ref-type="table-fn"}/13.3[\*\*](#tf2-2){ref-type="table-fn"}   vs placebo
                                                                                 telmisartan 80             153/100                               13.7[\*\*](#tf2-2){ref-type="table-fn"}/8.7[\*\*](#tf2-2){ref-type="table-fn"}    vs telmisartan 80
                                                                                 HCTZ 12.5                  153/100                               12.3[\*\*](#tf2-2){ref-type="table-fn"}/8.1[\*\*](#tf2-2){ref-type="table-fn"}    vs HCTZ 12.5
                                                                                 telmisartan 40/HCTZ 12.5   154/100                               7.2[\*](#tf2-1){ref-type="table-fn"}/3.3^ns^                                      vs telmisartan 40/HCTZ 12.5
                                         telmisartan 40/HCTZ 12.5 \[8\]          placebo                    154/100                               14.3[\*\*](#tf2-2){ref-type="table-fn"}/10.0[\*\*](#tf2-2){ref-type="table-fn"}   vs placebo
                                                                                 telmisartan 40             153/100                               12.3[\*](#tf2-1){ref-type="table-fn"}/3.3                                         vs telmisartan 40
                                                                                 HCTZ 12.5                  153/100                               5.1[\*](#tf2-1){ref-type="table-fn"}/4.8[\*](#tf2-1){ref-type="table-fn"}         vs HCTZ 12.5
  ([@b28])              346              telmisartan 40-80/HCTZ 12.5-25 \[26\]                              166/102                               20.9[\*\*](#tf2-2){ref-type="table-fn"}/14.4[\*\*](#tf2-2){ref-type="table-fn"}   vs baseline
                                                                                                                                                  7.2[\*](#tf2-1){ref-type="table-fn"}/6.0[\*](#tf2-1){ref-type="table-fn"}         vs telmisartan monotherapy
                        174              atenolol 50-100/HCTZ 12.5-25 \[26\]                                165/101                               16.7[\*\*](#tf2-2){ref-type="table-fn"}/13.3[\*\*](#tf2-2){ref-type="table-fn"}   vs baseline
                                                                                                                                                  6.6[\*](#tf2-1){ref-type="table-fn"}/3.5[\*](#tf2-1){ref-type="table-fn"}         vs atenolol monotherapy
  ([@b35])              139              telmisartan 20-80/HCTZ 0-25 \[26\]                                 181/102                               22.1^NR^/12.8^NR^                                                                 vs baseline
                                                                                                                                                  15.5^NR^/10.0^NR^                                                                 vs telmisartan 20-80 monotherapy
                        139              enalapril 5-20/HCTZ 0-25 \[26\]                                    177/100                               20.1^NR^/11.4^NR^                                                                 vs baseline
                                                                                                                                                  12.7^NR^/8.0^NR^                                                                  vs enalapril 5-20 monotherapy
  ATHOS Study([@b56])   497              telmisartan 80/HCTZ 12.5 \[6\]          amlodipine 10/HCTZ 12.5    145/81 (ABPM)                         19.3^NR^/NR                                                                       vs baseline
                                                                                                                                                  2.1[\*\*\*](#tf2-3){ref-type="table-fn"}/NR                                       vs amlodipine 10/HCTZ 12.5 over 24 h ABPM
                                         amlodipine 10/HCTZ 12.5                                            146/81 (ABPM)                         17.2^NR^/NR                                                                       vs baseline

**Notes:** NR not reported

p \< 0.05 vs comparator

p \< 0.01 vs comparator

p \< 0.001 vs comparator.

**Abbreviations:** ABPM, ambulatory blood pressure; HCTZ, hydrochlor othiazide; SBP/DBP, systolic/diastolic blood pressure.

When compared with other antihypertensive such as atenolol ([@b29]), amlodipine ([@b56]), or enalapril ([@b35]) given alone or in combination with hydrochlorothiazide, long-term studies demonstrated that telmisartan alone or combined with hydrochlorothiazide is at least as effective in treating high BP in patients with mild to moderate hypertension as these other drugs.

Thus, for example, the antihypertensive efficacy and tolerability of two doses of telmisartan and of the beta-blocker atenolol were compared in patients with mild to moderate hypertension in a 26-week multicenter, randomized, double-blind, double-dummy, parallel-group trial ([@b29]). This study was conducted in 520 men and women aged 22--79 years with morning mean supine DBP between 95 and 114 mmHg and SBP \<210 mmHg after a 2- to 3-week placebo run-in period. These patients were randomized in a 2:1 ratio to telmisartan (40 mg titrated to 80 mg or to 120 mg) or atenolol (50 mg titrated to 100 mg) in order to obtain a DBP ≤90 mmHg or a decrease of DBP from baseline of ≥10 mmHg (primary efficacy end point). Open-label hydrochlorothiazide 12.5 or 25 mg was added if needed according to a predefined titration rule. At the end of the study, 84% of the telmisartan and 78% of the atenolol-treated patients had achieved the primary end point (difference not statistically significant), The final reduction in SBP/DBP was 20.9/14.4 mmHg with telmisartan and 16.7/13.3 mmHg with atenolol; only the difference in SBP between both regimen was significant (p = 0.005). By week 26, 32% of the telmisartan and 28% of the atenolol patients required hydrochlorothiazide. For these patients, additional mean reductions in supine SBP/SDP of 7.2/6.0 mmHg were observed when the diuretic was added to telmisartan therapy, and 6.6/3.5 mmHg when hydrochlorothiazide was added to atenolol therapy ([@b29]).

Some studies have compared the efficacy of the ARB-diuretic therapy with other combinations in older patients. The ATHOS study has been designed to compare the changes in 24-hour ambulatory BP in 872 elderly with predominantly systolic hypertension receiving either telmisartan 80 mg/hydrochlorothiazide 12.5 mg or amlodipine 10 mg/hydrochlorothiazide 12.5 mg in a prospective, randomized, open-label, blinded-end point trial. The results of this study ([@b56]) showed that telmisartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide changed SBP for the last 6 hours of the dosing interval by −18.3 and −17.4 mmHg, respectively (p = 0.2520). However, telmisartan/hydrochlorothiazide provided significantly greater reductions compared than amlodipine/hydrochlorothiazide over the 24-hour period (−19.3 and −17.2 mmHg, respectively; p = 0.001) and provided higher SBP control rates (65.9% and 58.3%, respectively; p = 0.0175). Treatment effects were similar across age groups and in both men and women ([@b56]).

On other hand, when compared with enalapril in elderly patients (65 years and over) in a 26-week, multicenter, double-blind, parallel-group, dose-titration study ([@b35]), no significant difference were observed in mean changes from baseline both in supine DBP (−12.8 mmHg for telmisartan and −11.4 mmHg for enalapril) or SBP (−22.1 mmHg and −20.1 mmHg, respectively) at trough, and both regimens provided effective BP lowering over the 24-hour dosing interval, as determined by ambulatory BP monitoring. Both regimens were well tolerated; however, the incidence of treatment-related cough was significantly higher with enalapril than with telmisartan (16 vs 6.5%).

In another prospective, double-blind, randomized study ([@b3]), enalapril and telmisartan were compared in patients with type 2 diabetes and early nephropathy. Two hundred and fifty patients with normal levels of glomerular filtration rate (\>90 mL/min per 1.73 m^2^ of body-surface area) were enrolled and receive either telmisartan 80 mg or enalapril 20 mg. Hydrochlorothiazide was given as concomitant therapy in more than 50% of patients in each group. After 5 years of treatment, the adjusted mean reduction in SBP was 6.9 mmHg with telmisartan and 2.9 mmHg with enalapril (95% CIl, −8.5 to 0.5 mmHg, not significant). There was also no significant difference between groups in DBP mean difference. Of note, the primary end point of this study was the change in glomerular filtration rate (GFR) from baseline to the last available value during the five years of treatment. GFR decreased by 17.9 mL/min per 1.73 m^2^ of body-surface area with telmisartan compared with 15.0 mL/min per 1.73 m^2^ of body-surface area with enalapril, with a treatment difference of 2.6 mL/min. This difference was not significant ([@b3]).

Several other clinical studies have assessed the renal protective effect of telmisartan ([@b4]). [@b85] recently published a substudy of the Angiotensin II Receptor Antagonist Micardis in Isolated Systolic hypertension (ARAMIS) Study in which they investigated the reduction in urinary albumin excretion in patients with isolated systolic hypertension (ISH) unselected for albuminuria. This study showed that telmisartan 20--80 mg induced a significantly greater decrease in urinary albumin excretion than hydrochlorothiazide 12.5 mg, irrespective of the baseline UAE, and despite comparable reductions in SBP with both drugs.

Of note, based on the results of these studies and on the previous data from the RENAAL ([@b12]), IDNT ([@b43]), and IRMA II studies ([@b62]), the telmisartan renoprotective study from incipient nephropathy to overt nephropathy (INNOVATION) has been initiated ([@b47]). This prospective, randomized, double-blind forced-titration, parallel-group, placebo-controlled study compares a high and low dose of telmisartan in 1800 hypertensive or normotensive Japanese patients. It will assess whether telmisartan provides clinical benefits in hypertensive or normotensive patients with diabetes mellitus and diabetic nephropathy. This study has recently been completed and should be presented in 2006. In the same group of clinical studies (the PROTECTION trial program \[[@b88]\]), two sister trials, VIVALDI in Europe and AMADEO in North America, will compare the potential benefits of telmisartan and valsartan (VIVALDI) ([@b8]) or losartan (AMADEO) in the progression of renal disease in patients with diabetes and nephropathy. These two studies will be completed in early 2007.

Besides the antihypertensive effect of telmisartan and its potential ability to protect the kidney, telmisartan was also recently shown to be active in improving metabolic parameters, such as insulin resistance in hypertensive patients with coexisting type 2 diabetes or metabolic syndrome ([@b4]). However, none of these studies ([@b20], [@b21]; [@b55]; [@b85]; [@b72]) involved patients under concomitant therapy with hydrochlorothiazide.

Finally, the ability of telmisartan to reduce left ventricular hypertrophy (LVH) has been shown by several studies assessing left ventricular thickness or left ventricular mass as primary end point in mild to moderate hypertensive patients ([@b4]; Goebel et al 2006). A meta-analysis has identified differences in the ability of different classes of anti-hypertensive agents to prevent or revert LVH, with agents that target the RAS appearing superior to other agents, such as beta-blockers and diuretics ([@b23]). In this context, in a recent 12-month, double-blind study in 69 patients with mild to moderate hypertension, left ventricular mass index (LVMI) was significantly reduced from baseline with once-daily telmisartan 80 mg (141 vs 125 g/m^2^; p \< 0.001), whereas there was little change in patients receiving once-daily hydrochlorothiazide 25 mg (139 vs 135 g/m^2^) ([@b30]). The additional activity of telmisartan may probably be explained by the sustained BP control and the non-hemodynamic effects of targeting the RAS. The ultimate proof of the clinical value of telmisartan on reducing LVH will be provided by the outcome trials ONTARGET/TRANSCEND ([@b79]) and PROTECTION ([@b88]) which will clarify the cardioprotective role of telmisartan in in high-risk patients whose BP is well controlled.

Long-term exposure to telmisartan/hydrochlorothiazide
=====================================================

Two open-label extension studies have been performed to assess the long-term efficacy and tolerability of telmisartan 40--80 mg administered once daily alone or in association with hydrochlorothiazide (12.5--25 mg). One study provided results over a 1-year treatment period ([@b58]) and in the second study, data were gathered for up to 4 years ([@b28]).

In Neutel's study, 483 patients had their treatment with telmisartan 80 mg/day titrated over 1 year with stepwise addition of hydrochlorothiazide 12.5 mg or 25 mg, and/or other antihypertensive drugs to achieve a DBP \<90 mmHg ([@b58]). At the final visit, DBP control was achieved in 70.0% (194/277) of patients in the telmisartan monotherapy group and by 56%, 55%, and 65% of the patients receiving telmisartan/hydrochlorothiazide 80/12.5 mg/day, 80/25 mg/day, or telmisartan 80 mg plus another antihypertensive with or without the hydrochlorothiazide (12.5 or 25 mg). Progressively greater BP reductions occurred with the sequential addition of hydrochlorothiazide and other antihypertensives. All treatments were well tolerated ([@b58]).

The second long-term study assessing the efficacy and tolerability of telmisartan combined with hydrochlorothiazide lasted 4 years ([@b28]). This open-label extension study of 4 controlled trials involved 888 patients with mild to moderate hypertension. Patients received telmisartan 40--80 mg once daily with add-on hydrochlorothiazide (12.5--25 mg) if necessary and/or other antihypertensives excluding other ARBs. The main goal was to lower supine DBP below 90 mmHg. Almost 80% of the patients (701/888) completed the trial with a median exposure of 1184 days (\>3 years). The proportion of responders was 89% in the telmisartan monotherapy (40 or 80 mg) treatment category after 8 weeks of treatment. However, this percentage dropped years to 59% after 3 years, indicating that about one-third of patients initially responsive to telmisartan alone required additional therapy over time. With the addition of hydrochlorothiazide, in most cases 25 mg qd, the primary end point was reached in 75% of the patients who became unresponsive to the monotherapy. Most adverse events were of mild to moderate intensity and unrelated to treatment ([@b28]).

Safety and tolerability
=======================

With an adverse-event profile closely resembling that of placebo, telmisartan, like other ARBs, is characterized by a very high safety and tolerability, which has been confirmed in several clinical trials ([@b27]; [@b4]) but also in a large, 6-month, post-marketing surveillance study enrolling 19,870 patients ([@b54]). The profiles of adverse events observed in these studies were similar in frequency and severity. Most adverse effects were mild and transient and occurred with a similar incidence in the placebo groups. Headache and dizziness were the most frequent adverse events. The tolerability and safety record of telmisartan is consistent across a wide range of patient demographic variables such as age, sex, and ethnic group ([@b4]). Neither the dry cough associated with ACE inhibitors nor the edema associated with calcium channel blockers (CCBs) has been observed with telmisartan treatment ([@b89]).

The safety and tolerability of telmisartan/hydrochlorothiazide was investigated in most of the above-mentioned studies ([@b35]; [@b38]; [@b29]; [@b51], [@b52]; [@b58]; [@b40]; [@b38]). The overall tolerability profile was good, the incidence of adverse effects in the combination groups being similar to that observed in placebo-treated groups. For example, in the factorial design trial with combinations of telmisartan, hydrochlorothiazide, and placebo ([@b52]), where all the 818 randomized patients were included in the safety analysis, adverse events were reported in 96 of 209 (45.9%) patients receiving telmisartan monotherapy, 61 of 121 (50.4%) receiving hydrochlorothiazide monotherapy, 199 of 414 (48.1%) receiving combination therapy, and 31 of 74 (41.9%) receiving placebo. Most adverse effects were mild in intensity and transient and did not require discontinuation of the therapy. No unexpected serious adverse events have been observed and adverse experiences have been limited to those that have been previously reported with telmisartan and/or hydrochlorothiazide. Thus, adverse events occurring in more than 2% of telmisartan/hydrochlorothiazide-treated patients were dizziness (5%), sinusitis and upper respiratory tract infection (4%--8%), fatigue (3%), influenza-like symptoms (2%), and gastrointestinal problems (nausea 2%, diarrhea 3%). In the same study, hydrochlorothiazide caused a dose-related decrease in serum potassium. Combination with telmisartan tended to offset the effects of hydrochlorothiazide on serum potassium levels ([@b52]) ([Figure 1](#fig1){ref-type="fig"}).

![Telmisartan plus hydrochlorothiazide (HTCZ) combined therapy offsets the effects of hydrochlorothiazide on serum potassium levels (derived from data [@b52]).](vhrm0303-265-01){#fig1}

Finally, a meta-analysis of data collected from 34 randomized trials also concluded that the incidence of treatment-related adverse events is similar in placebo-treated (10.5% n = 819) patients and patients receiving either telmisartan 10--60 mg/day (12%, n = 6575) or telmisartan/hydrochlorothiazide 10--160/6.25--25 mg/day (12.8%, n = 2180) ([@b48]). Of note, the incidence of treatment-related adverse events per patient per treatment year was higher in patients receiving placebo (1.02) than in patients on telmisartan monotherapy (0.20) or on combined telmisartan/hydrochlorothiazide therapy (0.18) (statistical analysis not reported) ([@b48]). As with telmisartan alone, the most commonly reported adverse events in patients receiving telmisartan and hydrochlorothiazide were dizziness and headache and fatigue. In the same study, serious adverse events occurred less frequently in placebo recipients (1.1%) than in telmisartan-treated patients (5.6 % with hydrochlorothiazide and 4.3% without hydrochlorothiazide, respectively). However, per patient per treatment year, the incidence was similar in all groups ([@b48]). Treatment-related hyperuricemia and hypokalemia occurred only in 5 and 6 patients, respectively, receiving combination therapy ([@b48]).

Unfortunately, we have to emphasize that most of studies that have investigated the effect and the safety of the telmisartan/hydrochlorothiazide association have been short and medium term, and results of the longest ONTARGET and PROTECTION studies are not yet available. Generally, most of the longest prospective randomized trials in hypertension last only 4--6 years and therefore provide little if any information on long-term safety, particularly for diuretics with or without combination with other antihypertensive drugs. Many patients are exposed to BP-lowering drugs for many decades, and drug-induced changes could be cumulative (Grosmann and Messerli 2006). This is potentially true with the adverse metabolic effects that are seen with the diuretics. However, a combination with hydrochlorothiazide blunted the deleterious effect of diuretics decreasing the development of new-onset diabetes in shorter-term experiments as observed in LIFE, SCOPE, and VALUE trials ([@b24]). Therefore we have to wait for cohort studies investigating morbidity and mortality of hypertensive patients which require an intervention on the RAS system to fully characterize the long-term protective effect of combining an ARB with a thiazide diuretic.

In all studies, adverse events occurred at approximately the same rate in men and women, older and younger patients ([@b35]; [@b56]), black and non-black patients ([@b51]), and diabetic or non-diabetic ([@b27]). Long-term combination therapy is also well-tolerated as already mentioned in the 4-year extension trial published by Freytag et al ([@b28]).

Compared with other combined therapy, patients treated with telmisartan plus hydrochlorothiazide in the ATHOS study experienced fewer treatment-related adverse events than patients receiving amlodipine plus hydrochlorothiazide (8% vs 33%; p \< 0.0001), with the incidence of peripheral edema being significantly lower in the telmisartan combination therapy (1.2% vs 24.3%; p \< 0.0001) ([@b56]) ([Figure 2](#fig2){ref-type="fig"}). Relative to ACEIs, the incidence of treatment-related adverse events was similar for telmisartan and enalapril ([@b35]). However, as already mentioned above, more than twice as many patients taking enalapril experienced cough (16 vs 6.5%), which is believed to be caused by an accumulation of bradykinin that is not degraded in patients treated with an ACE inhibitor ([@b34]) ([Figure 3](#fig3){ref-type="fig"}).

![Drug-related adverse events, incidence of peripheral edema, and discontinuation rates in the ATHOS Study (derived from data of [@b56]).\
**Abbreviations:** HTCZ, hydrochlorothiazide.](vhrm0303-265-02){#fig2}

![Drug-related adverse events, incidence of cough, and discontinuation rates in a study comparing telmisartan plus hydrochlorothiazide (HTCZ) with enalapril plus hydrochlorothiazide in patients with mild to moderate hypertension (derived from data of [@b35]).](vhrm0303-265-03){#fig3}

Persistence on treatment
========================

The more active drug will never be effective if it is not taken by the patient, and poor compliance is certainly an important cause of inadequate BP control. Several patient-related and physician-related parameters can affect drug adherence. There is, however, good evidence that drug-related issues can also interfere with the adherence to treatment. Thus the treatment complexity, the frequency of dosing, as well as the tolerability profile of the drugs are important determinants of drug adherence.

One very common reason why patients do not comply with the prescription is the fact that they have to take several different medications with varying frequencies of dosing ([@b65]). This is an important contributory factor to poor compliance particularly in elderly patients ([@b98]). Therefore, efforts should been made to simplify drug regimens, and one appropriate intervention is to reduce the frequency of the drug administration as well as the number of agents to be taken. Indeed, a once-daily regimen induces a better compliance than a twice-daily regimen. This can be achieved using long-acting agents and fixed-dose combinations which reduce the number of daily tablets. Several studies performed using ambulatory BP monitoring have shown that telmisartan shifts the entire BP profile to lower levels including in the early morning period ([@b61]; [@b41]). Moreover, the use of long-acting antihypertensive drugs such as telmisartan may prevent the rise in BP induced by a missed dose and may improve the 24-hour BP control even in the early morning hours before the next dose is taken ([@b96]).

In a recent meta-analysis presented at the European Meeting of Hypertension, the efficacy of fixed-dose combinations to improve patient compliance therapy was compared with free-drug component regimens in patients with chronic disease ([@b2]). Nine studies that reported medication compliance/adherence or persistence when using fixed-dose combinations versus free-drug combinations were selected, of which 4 dealt with antihypertensive agents. In the hypertension studies, the authors showed that fixed-dose combinations of antihypertensive drugs (amlodipine plus benazepril ([@b78]), lisinopril plus hydrochlorothiazide or enalapril plus hydrochlorothiazide ([@b22]), and ARBs plus diuretic ([@b2])) improve compliance to medication by more than 50% when compared with free-drug combinations ((OR 1.54, 95% CI 1.42--1.66). Such improvement in drug adherence should have an important impact on clinical outcomes.

Another reason why hypertensive patients do not take their pills regurlarly is that they develop side-effects while the hypertension is usually asymptomatic ([@b13]). In this context, the excellent tolerability profile of ARBs including telmisartan combined with hydrochlorothiazide is a potential advantage. Indeed, studies that have analyzed patterns of compliance and persistence (defined as continuing therapy with the originally prescribed antihypertensive drug) have shown that both are intimately linked to tolerability ([@b36]; [@b18]; [@b97]). In a study of persistence that evaluated prescription refill data from 21,723 patients enrolled in a large pharmaceutical management organization ([@b7]), the percentage of patients continuing initial ARB therapy was substantially higher at 12 months' follow-up than the percentage continuing therapy with ACEIs, calcium antagonists, beta-blockers, or thiazide diuretics (64% vs 58%, 50%, 43%, and 38%, respectively); and patients taking an ARB were more likely to continue with their initial therapy than those taking an ACEI, a calcium antagonist, a beta-blocker, or a thiazide diuretic ([@b7]). Another study determined whether the stay-on-therapy (persistence) patterns observed in a previous analysis at one year were maintained over a 4-year period. Significantly more patients whose initial therapy was based on an ARB (losartan in this case) had continued with this treatment at 24 months (p \< 0.007) and at 36 months (p \< 0.01) compared with patients initially given drugs from other antihypertensive class. At 48 months, half (50.9%) of the original losartan-prescribed group was still taking the initial agents whereas 36.5% of the other antihypertensive cohorts remained on their initial drug class ([@b18]). In addition another study assessing persistence with antihypertensive therapy and discontinuation patterns in patients newly dispensed different antihypertensive drug classes in a natural Canadian population-based setting showed that compared with ARBs, the likelihood of discontinuing therapy over the 39-month study period was significantly higher for ACEIs (HR 1.29; 95% CI 1.16--1.43), calcium antagonists (HR 1.42; 95% CI 1.27--1.60), beta blockers (HR 1.62; 95% CI 1.45--1.80), and diuretics (HR 1.92; 95% CI 1.73--2.14). In the year following treatment discontinuation, between 54% and 75% of patients initiated a second course of treatment. Patients initiated on an ARB had a significantly higher likelihood of starting a new course of therapy after a first treatment discontinuation, compared with all other agents ([@b11]). In the ATHOS study discussed before, the discontinuation rate was two-fold higher in the amlodipine-hydrochlorothiazide group than in the telmisartan/hydrochlorothiazide group (11.3 compared with 5.0%; p \< 0.001), mainly due to peripheral edema ([@b56]).

Conclusion
==========

Blockade of the RAS with selective AT~1~ receptor antagonists is recognized as an effective mean to lower BP in hypertensive patients. Among AT~1~ receptor antagonists, telmisartan is characterized by a very long half-life. This enables smooth BP control over 24 hours using a once-daily administration and might result in potential clinical advantages such as greater compliance, sustained BP control, maintenance of control regardless of missing a dose, and reduced risk of cardiovascular events during the early morning hours. The preclinical data demonstrating the partial PPAR-γ agonistic activity of telmisartan are of great interest considering the actual epidemiological trends of diabetes and obesity. However, whether these in vitro properties translate into real clinical benefits still needs clinical confirmation in large groups of patients.

The combination of telmisartan with hydrochlorothiazide is logical and also very effective. In accordance with past experiences using other compounds, several controlled studies have demonstrated that combining telmisartan with a low-dose thiazide is superior in lowering BP than either telmisartan or hydrochlorothiazide alone. Moreover, the excellent tolerability profile of the ARB is not affected by the addition of a low-dose thiazide.

Finally, fixed-dose combinations are increasingly used in clinical practice in order to achieve the therapeutic goals defined by most national and international guidelines. The use of drugs combinations will probably increase further in future with the introduction of fixed-dose combinations as possible first-step therapies for hypertension according to European guidelines ([@b17]). American guidelines proposed the use of fixed-dose combination as initial therapy in patients with stage 2 and 3 hypertension ([@b16]). Since the AT~1~ receptor antagonist/thiazide diuretic combination is an effective and well-tolerated drug association, one might expect that the use of these combinations including that of telmisartan and hydrochlorothiazide will increase steadily over the next 5 years.
